Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,170.00
Bid: 11,500.00
Ask: 12,270.00
Change: 0.00 (0.00%)
Spread: 770.00 (6.696%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,170.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET PRE-OPEN: Phoenix in record half-year cash generation

Mon, 15th Aug 2022 07:47

(Alliance News) - Stock prices in London are seen opening higher on Monday, though equities in China were showing signs of late weakness after poorer than expected retail sales data from the world's second-largest economy.

IG futures indicate the FTSE 100 index is to open 32.7 points higher, 0.4%, at 7,533.59. The blue chip index closed up 34.98 points, or 0.5%, at 7,500.89 on Friday. It added 0.8% last week.

In early UK corporate news, Phoenix Group offered a bullish cash generation outlook for 2022, after a "strong" first half, coal miner Thungela posted a substantial revenue hike, while ingredients supplier Treatt issued a profit warning.

Phoenix Group reported a "record" first half for cash generation, lending it confidence for the rest of the year.

"Phoenix delivered against all of its key objectives in H1, with a record set of financial results and clear strategic progress made. We have delivered further organic growth and also announced the cash funded acquisition of Sun Life of Canada UK. This will support us in delivering a dividend that is 'sustainable and grows over time'," the London-based insurance services provider said.

Phoenix's total revenue climbed 28% to GBP2.69 billion from GBP2.10 billion a year earlier.

However, its pretax loss widened to GBP1.65 billion from GBP454 million. Its bottom line was hit by a GBP31.61 billion net investment loss, swinging from income of GBP8.11 billion a year earlier.

Phoenix hailed its "record" first half cash generation of GBP950 million, up from GBP872 million a year earlier.

It is now "confident of delivering at the top-end of our GBP1.3 billion to GBP1.4 billion target range for the year".

The FTSE 100 listing lifted its interim payout to 24.8 pence per share from 24.1p.

AstraZeneca said its Enhertu drug met its primary endpoint in a breast cancer trial.

Enhertu showed a "meaningful improvement" in progression-free survival, the amount of time a patient lives without the disease getting worse.

The trial involved sufferers of human epidermal growth factor receptor 2-positive unresectable and/or metastatic breast cancer. Participants had been previously treated with trastuzumab emtansine, an existing cancer therapy.

Unresectable is when the disease cannot be removed through surgery, and metastatic is when it spreads to distant parts of the body.

Coal miner Thungela hailed a record first half performance.

Revenue in the six months to June 30 more than doubled to ZAR26.18 billion, about GBP1.33 billion, from ZAR10.05 billion.

It declared a ZAR60 interim dividend per share, having not declared one a year earlier.

"Demand for affordable energy sources such as thermal coal escalated amid the energy security crisis which was exacerbated by the escalation of the Russia-Ukraine conflict. Coupled with supply constraints in major coal producing regions, this resulted in the price of thermal coal increasing to unprecedented levels," Thungela said.

"Notwithstanding the impact of the rail performance on export equity sales volumes, we achieved record adjusted operating free cash flow of ZAR8.9 billion."

Thungela was hived off from parent Anglo American last year in June.

Elsewhere in London, Digital 9 Infrastructure set out plans to move to the Premium Segment of the Main Market, qualifying it for FTSE index inclusion.

The digital infrastructure investor said: "As the company grows, the board believes that DGI9 will benefit over time from the migration with an increase of its profile as an investment company, diversification of the company's share register with access to blue chip UK and international investors as well as from potential FTSE index inclusion. The migration is subject to the company meeting the relevant eligibility criteria under the listing rules and approval by the FCA. The company will provide an update in due course."

Digital 9 currently has a market capitalisation of GBP972.5 million, ahead of roughly 65 FTSE 250 constituents, including the likes of Currys, Moonpig, JD Wetherspoon, Aston Martin and Greencore.

Next Fifteen Communications said its acquisition of advertising agency M&C Saatchi has received two key regulatory approvals.

It has received approvals under the UK National Security & Investment Act 2021 and the Australian foreign investment regulatory framework.

Backing from the Committee on Foreign Investment in the US remains. Next Fifteen expects this to be received early in the fourth quarter.

Natural extracts and ingredients supplier Treatt warned on annual profit, amid accelerating inflation, weaker margins due to foreign exchange volatility and Covid-19-hit subsidiary in China.

Treatt now expects pretax profit before exceptional items to land between GBP15.0 million and GBP15.3 million for the full-year.

In its results for the half-year ended March 31, it said it was on track to deliver profit in line with consensus of GBP21.7 million.

In Tokyo on Monday, the Nikkei 225 ended 1.1% higher, while the S&P/ASX 200 in Sydney rose 0.5%. In China, the Shanghai Composite was down 0.1% in late trade, though the Hang Seng in Hong Kong was down 0.5%.

Factory output and retail sales in China edged up in July but were weaker than analysts' expectations, official data showed Monday, as a Covid-19 resurgence and property market jitters cast a pall over hopes for a stronger economic recovery.

The world's second-biggest economy saw a bounce in business activity as some coronavirus restrictions eased in June, but the boost is fading and Beijing remains welded to a zero-Covid policy of snap lockdowns and long quarantines, which has battered sentiment.

But for July, China's industrial production rose 3.8% on-year, down from a 3.9% jump in June, the National Bureau of Statistics said Monday.

Retail sales grew at a slower-than-expected 2.7% from a year ago, down from 3.1% in June, while the urban unemployment rate fell to 5.4%, the NBS said.

In Japan, the economy expanded in the three months to June, official data showed Monday, after the government lifted Covid-19 curbs on businesses.

The world's third-largest economy grew 0.5% quarter-on-quarter due to stronger consumption and capital investment.

While the country never imposed strict stay-at-home orders during the pandemic, the government in March lifted virus restrictions primarily targeting business opening hours.

The pound was quoted at USD1.2104 early Monday in London, down from USD1.2121 late Friday. The euro stood at USD1.0239, down from USD1.0248. Against the yen, the dollar was trading at JPY133.29, down from JPY133.63.

Brent oil was quoted at USD97.19 a barrel early Monday, down from USD97.91 at the London equities close on Friday. Gold was quoted at USD1,791.62 an ounce, down from USD1,797.13.

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more
25 Apr 2024 09:18

TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth

(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.

Read more
25 Apr 2024 09:12

LONDON MARKET OPEN: Anglo American jumps on takeover bid from BHP

(Alliance News) - Stock prices in London opened mixed on Thursday, as investors cautiously eye data on the health of the US economy.

Read more
25 Apr 2024 08:38

AstraZeneca blows past analysts' estimates for Q1

(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.

Read more
25 Apr 2024 07:56

REPEAT: Miner Anglo American reviews takeover bid from rival BHP

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
25 Apr 2024 07:52

Sanofi profit slips on generic competition and currency effects

April 25 (Reuters) - Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.